The global veterinary monoclonal antibodies market is projected to reach USD 3.06 billion by 2030, from USD 1.70 billion in 2025, with a CAGR of 12.4%. The market is experiencing significant growth, driven by the expanding companion animal population and rising pet ownership. Growing concerns about chronic diseases have further boosted the demand for veterinary treatments. Government and animal welfare organizations actively promote awareness campaigns, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals. However, the market faces challenges such as rising pet care costs, which can limit treatment adoption. Furthermore, strict regulatory guidelines and lengthy approval times for drugs further restrain market growth. Despite these hurdles, expanding therapeutic indications beyond dermatology and osteoarthritis continues to create new market opportunities.
“By animal type, the canine segment held the highest share in 2024.”
The canine segment held the largest market share in 2024, driven by rising pet dog ownership and increasing spending on animal healthcare. Dogs are highly prone to skin conditions such as allergies, fungal infections, and ectoparasitic infestations, which require frequent dermatological treatments. The growing trend of pet humanization and the demand for premium veterinary care further support market growth. Additionally, advancements in dermatological treatments, including biologics and targeted monoclonal antibody therapies, improve treatment outcomes for dogs, solidifying the segment’s dominance in the market.
“By route of administration, the subcutaneous segment is projected to record the highest CAGR between 2025 and 2030.”
The subcutaneous segment is expected to grow at the fastest rate during the forecast period due to its ease of administration and better pet owner compliance. Rising veterinary recommendations for systemic treatments over topical solutions and the ongoing development of new monoclonal antibodies targeting infectious diseases are increasing demand. Moreover, innovations in monoclonal antibodies targeting infectious diseases further support the segment’s growth in the veterinary monoclonal antibodies market.
“By product, cytopoint was the leading segment in 2024.”
The cytopoint segment held the largest market share in 2024, driven by its status as the first and only FDA- and EMA-approved monoclonal antibody therapy for treating canine atopic dermatitis. Additionally, the high prevalence of atopic dermatitis in dogs has increased demand for cytopoint due to its proven efficacy, safety profile, and rising adoption by veterinarians. The growing willingness of pet owners to invest in advanced veterinary treatments has further fueled market growth.
“By therapy type, dermatology surpassed other segments in 2024.”
The dermatology segment held the largest market share in 2024 due to the rising prevalence of chronic diseases such as atopic dermatitis in dogs. Additionally, growing awareness of advanced treatment options like Cytopoint by Zoetis (US) has gained significant traction due to its long-lasting relief and minimal side effects in treating allergic and atopic dermatitis in dogs. The willingness to spend on pet healthcare has further driven this market growth.
“By end user, veterinary hospitals/specialty centers are expected to exhibit the fastest growth during the forecast period.”
Veterinary hospitals/specialty centers are expected to grow at the fastest rate, fueled by the rise in veterinary visits and the availability of specialized pet healthcare services. These facilities offer comprehensive treatment options, including advanced diagnostics, prescription medications, and surgical procedures for various conditions. Additionally, pet insurance coverage for dermatological treatments encourages pet owners to seek veterinary care, boosting demand in this segment.
“North America accounted for the largest share in 2024.”
North America held the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in R&D for innovative monoclonal antibody therapies. Rising awareness about pet health, along with increasing spending on veterinary care, also drives market growth. The growing demand for premium pet care products further contributes to North America’s dominance in the global veterinary monoclonal antibodies market.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1 – 75%, Tier 2 – 15%, and Tier 3 – 10%
• By Designation: C-level – 30%, D-level – 23%, and Other Designations – 47%
• By Region: North America – 35%, Europe – 20%, Asia Pacific – 25%, Latin America – 13%, and Middle East & Africa – 7%
The major players operating in the veterinary monoclonal antibodies market are Zoetis Services LLC (US), Elanco (US), and Merck & Co., Inc. (US).
Research Coverage
This report examines the veterinary monoclonal antibodies market based on animal type, product, therapy area, route of administration, end user, and region. It also considers factors such as drivers and restraints that influence market growth. The report highlights opportunities and challenges within the market and offers details about the competitive landscape for market leaders. Additionally, it analyzes micro markets concerning their individual growth trends and forecasts the revenue of market segments across five main regions and their respective countries.
Reasons to Buy this Report
The report can assist both established firms and new or smaller companies in understanding the market dynamics, which can help them increase their market share. Companies purchasing the report may employ one or a combination of the five strategies listed below.
This report provides insights into the following points:
• Analysis of key drivers (increased prevalence of chronic diseases in animals, innovation in monoclonal antibodies targeting infectious diseases, rise in companion animal population and pet ownership, growth in veterinary healthcare expenditure), restraints (regulatory hurdles and long approval timelines, high cost of development and treatment), opportunities (expanding therapeutic indications beyond dermatology and osteoarthritis, novel administration routes for monoclonal antibodies, rising strategic developments among market players in development of veterinary monoclonal antibodies), and challenges (emerging safety concerns and adverse events reporting, and limited species-specific knowledge) influencing the growth of veterinary monoclonal antibodies market
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the veterinary monoclonal antibodies market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of monoclonal antibody treatments across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary monoclonal antibodies market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary monoclonal antibodies market
圖表清單 List of Tables & Figures
TABLE 1 VETERINARY MONOCLONAL ANTIBODIES MARKET: INCLUSIONS AND EXCLUSIONS 27
TABLE 2 VETERINARY MONOCLONAL ANTIBODIES MARKET: RESEARCH ASSUMPTIONS 41
TABLE 3 VETERINARY MONOCLONAL ANTIBODIES MARKET: RISK ANALYSIS 42
TABLE 4 PET (DOGS AND CATS) OWNERSHIP IN US, 2024 55
TABLE 5 INDICATIVE SELLING PRICE OF VETERINARY MONOCLONAL ANTIBODIES,
BY KEY PLAYER, 2024 (USD) 61
TABLE 6 INDICATIVE SELLING PRICE OF VETERINARY MONOCLONAL ANTIBODIES,
BY REGION, 2022–2024 (USD) 62
TABLE 7 VETERINARY MONOCLONAL ANTIBODIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 65
TABLE 8 VETERINARY MONOCLONAL ANTIBODIES MARKET: INNOVATIONS AND
PATENT REGISTRATIONS, 2023–2024 70
TABLE 9 IMPORT DATA FOR HS CODE 300214, BY COUNTRY,
2021–2024 (USD THOUSAND) 71
TABLE 10 EXPORT DATA FOR HS CODE 300214, BY COUNTRY,
2021–2024 (USD THOUSAND) 71
TABLE 11 VETERINARY MONOCLONAL ANTIBODIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 72
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 15 VETERINARY MONOCLONAL ANTIBODIES MARKET: PORTER’S FIVE FORCES ANALYSIS 78
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 81
TABLE 17 KEY BUYING CRITERIA, BY END USER 82
TABLE 18 VETERINARY MONOCLONAL ANTIBODIES MARKET: CURRENT UNMET NEEDS 82
TABLE 19 VETERINARY MONOCLONAL ANTIBODIES MARKET: PIPELINE ANALYSIS 83
TABLE 20 US-ADJUSTED RECIPROCAL TARIFF RATES 88
TABLE 21 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR VETERINARY MONOCLONAL ANTIBODIES MARKET 88
TABLE 22 IMPACT ON COUNTRY/REGION DUE TO US TARIFFS 89
TABLE 23 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 92
TABLE 24 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR CANINES, BY COUNTRY, 2023–2030 (USD MILLION) 93
TABLE 25 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR FELINES, BY COUNTRY, 2023–2030 (USD MILLION) 95
TABLE 26 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER ANIMALS,
BY COUNTRY, 2023–2030 (USD MILLION) 96
TABLE 27 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 98
TABLE 28 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR LOKIVETMAB, BY COUNTRY, 2023–2030 (USD MILLION) 99
TABLE 29 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR BEDINVETMAB,
BY COUNTRY, 2023–2030 (USD MILLION) 100
TABLE 30 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR FRUNEVETMAB,
BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 31 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR CANINE PARVOVIRUS MONOCLONAL ANTIBODY, BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 32 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR GILVETMAB, BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 33 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 34 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 105
TABLE 35 COMMERCIALLY AVAILABLE MONOCLONAL ANTIBODIES WITH SUBCUTANEOUS ROUTE OF ADMINISTRATION 106
TABLE 36 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 37 COMMERCIALLY AVAILABLE MONOCLONAL ANTIBODIES WITH INTRAVENOUS ROUTE OF ADMINISTRATION 107
TABLE 38 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 39 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 40 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA,
2023–2030 (USD MILLION) 111
TABLE 41 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 42 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR PAIN MANAGEMENT,
BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 43 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 44 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 45 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER THERAPY AREAS,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 46 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 119
TABLE 47 AVERAGE TOTAL AMOUNT SPENT PER HOUSEHOLD ON PETS IN US,
2023–2024 (USD) 119
TABLE 48 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY HOSPITALS/SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 49 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY CLINICS,
BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 50 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR VETERINARY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 51 VETERINARY MONOCLONAL ANTIBODIES MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 52 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY REGION,
2023–2030 (USD MILLION) 128
TABLE 53 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT) 131
TABLE 54 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 55 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 131
TABLE 56 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 132
TABLE 57 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 132
TABLE 58 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY THERAPY AREA, 2023–2030 (USD MILLION) 133
TABLE 59 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 133
TABLE 60 US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 134
TABLE 61 US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 134
TABLE 62 US: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 135
TABLE 63 US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA,
2023–2030 (USD MILLION) 135
TABLE 64 US: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 135
TABLE 65 CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 136
TABLE 66 CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 137
TABLE 67 CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 137
TABLE 68 CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 138
TABLE 69 CANADA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 138
TABLE 70 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (UNIT) 139
TABLE 71 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION 140
TABLE 72 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 140
TABLE 73 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 141
TABLE 74 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 141
TABLE 75 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 142
TABLE 76 EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 142
TABLE 77 GERMANY: KEY MACROECONOMIC INDICATORS 143
TABLE 78 GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 143
TABLE 79 GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 144
TABLE 80 GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 144
TABLE 81 GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 145
TABLE 82 GERMANY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION) 145
TABLE 83 FRANCE: KEY MACROECONOMIC INDICATORS 146
TABLE 84 FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 146
TABLE 85 FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 147
TABLE 86 FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 147
TABLE 87 FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 148
TABLE 88 FRANCE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 148
TABLE 89 UK: KEY MACROECONOMIC INDICATORS 149
TABLE 90 UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 149
TABLE 91 UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 150
TABLE 92 UK: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 150
TABLE 93 UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA,
2023–2030 (USD MILLION) 151
TABLE 94 UK: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 151
TABLE 95 ITALY: KEY MACROECONOMIC INDICATORS 152
TABLE 96 ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE
2023–2030 (USD MILLION) 152
TABLE 97 ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 153
TABLE 98 ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 153
TABLE 99 ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 154
TABLE 100 ITALY: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 154
TABLE 101 SPAIN: KEY MACROECONOMIC INDICATORS 155
TABLE 102 SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE
2023–2030 (USD MILLION) 155
TABLE 103 SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 156
TABLE 104 SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 156
TABLE 105 SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 157
TABLE 106 SPAIN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 157
TABLE 107 NETHERLANDS: KEY MACROECONOMIC INDICATORS 158
TABLE 108 NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 158
TABLE 109 NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 159
TABLE 110 NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 159
TABLE 111 NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY THERAPY AREA, 2023–2030 (USD MILLION) 160
TABLE 112 NETHERLANDS: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 160
TABLE 113 REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 161
TABLE 114 REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 161
TABLE 115 REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 162
TABLE 116 REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY THERAPY AREA, 2023–2030 (USD MILLION) 162
TABLE 117 REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 163
TABLE 118 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY PRODUCT, 2023–2030 (UNIT) 165
TABLE 119 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION 165
TABLE 120 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 166
TABLE 121 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 166
TABLE 122 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 167
TABLE 123 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY THERAPY AREA, 2023–2030 (USD MILLION) 167
TABLE 124 ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 168
TABLE 125 JAPAN: KEY MACROECONOMIC INDICATORS 169
TABLE 126 JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 169
TABLE 127 JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 169
TABLE 128 JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 170
TABLE 129 JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 170
TABLE 130 JAPAN: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 171
TABLE 131 CHINA: KEY MACROECONOMIC INDICATORS 171
TABLE 132 CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 172
TABLE 133 CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 172
TABLE 134 CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 173
TABLE 135 CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 173
TABLE 136 CHINA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 174
TABLE 137 INDIA: KEY MACROECONOMIC INDICATORS 174
TABLE 138 INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,
2023–2030 (USD MILLION) 175
TABLE 139 INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 175
TABLE 140 INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 176
TABLE 141 INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 176
TABLE 142 INDIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 177
TABLE 143 AUSTRALIA: KEY MACROECONOMIC INDICATORS 177
TABLE 144 AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 178
TABLE 145 AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 178
TABLE 146 AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 179
TABLE 147 AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 179
TABLE 148 AUSTRALIA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION) 180
TABLE 149 SOUTH KOREA: KEY MACROECONOMIC INDICATORS 180
TABLE 150 SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 181
TABLE 151 SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 181
TABLE 152 SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 182
TABLE 153 SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY THERAPY AREA, 2023–2030 (USD MILLION) 182
TABLE 154 SOUTH KOREA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION) 183
TABLE 155 NEW ZEALAND: KEY MACROECONOMIC INDICATORS 183
TABLE 156 NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 184
TABLE 157 NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 184
TABLE 158 NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 185
TABLE 159 NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY THERAPY AREA, 2023–2030 (USD MILLION) 185
TABLE 160 NEW ZEALAND: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION) 186
TABLE 161 REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 186
TABLE 162 REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 187
TABLE 163 REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 187
TABLE 164 REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY THERAPY AREA, 2023–2030 (USD MILLION) 188
TABLE 165 REST OF ASIA PACIFIC: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 188
TABLE 166 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (UNIT) 189
TABLE 167 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 168 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 190
TABLE 169 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 191
TABLE 170 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 191
TABLE 171 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY THERAPY AREA, 2023–2030 (USD MILLION) 192
TABLE 172 LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030 (USD MILLION) 192
TABLE 173 BRAZIL: KEY MACROECONOMIC INDICATORS 193
TABLE 174 BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 193
TABLE 175 BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 194
TABLE 176 BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 194
TABLE 177 BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 195
TABLE 178 BRAZIL: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 195
TABLE 179 MEXICO: KEY MACROECONOMIC INDICATORS 196
TABLE 180 MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION) 196
TABLE 181 MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 197
TABLE 182 MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 197
TABLE 183 MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA, 2023–2030 (USD MILLION) 198
TABLE 184 MEXICO: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2023–2030 (USD MILLION) 198
TABLE 185 REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 199
TABLE 186 REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 199
TABLE 187 REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 200
TABLE 188 REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY THERAPY AREA, 2023–2030 (USD MILLION) 200
TABLE 189 REST OF LATIN AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 201
TABLE 190 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY PRODUCT, 2023–2030 (UNIT) 202
TABLE 191 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ANIMAL TYPE, 2023–2030 (USD MILLION) 202
TABLE 192 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 203
TABLE 193 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 203
TABLE 194 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY THERAPY AREA, 2023–2030 (USD MILLION) 204
TABLE 195 MIDDLE EAST & AFRICA: VETERINARY MONOCLONAL ANTIBODIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 204
TABLE 196 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET 205
TABLE 197 VETERINARY MONOCLONAL ANTIBODIES MARKET:
DEGREE OF COMPETITION, 2024 208
TABLE 198 VETERINARY MONOCLONAL ANTIBODIES MARKET: REGION FOOTPRINT 214
TABLE 199 VETERINARY MONOCLONAL ANTIBODIES MARKET: ANIMAL TYPE FOOTPRINT 215
TABLE 200 VETERINARY MONOCLONAL ANTIBODIES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 215
TABLE 201 VETERINARY MONOCLONAL ANTIBODIES MARKET: THERAPY AREA FOOTPRINT 216
TABLE 202 VETERINARY MONOCLONAL ANTIBODIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 218
TABLE 203 VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 218
TABLE 204 VETERINARY MONOCLONAL ANTIBODIES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 219
TABLE 205 VETERINARY MONOCLONAL ANTIBODIES MARKET: DEALS,
JANUARY 2022–JUNE 2025 220
TABLE 206 VETERINARY MONOCLONAL ANTIBODIES MARKET: EXPANSIONS,
JANUARY 2022–JUNE 2025 221
TABLE 207 ZOETIS SERVICES LLC: COMPANY OVERVIEW 222
TABLE 208 ZOETIS SERVICES LLC: PRODUCTS OFFERED 223
TABLE 209 ZOETIS SERVICES LLC: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022−JUNE 2025 224
TABLE 210 ZOETIS SERVICES LLC: DEALS, JANUARY 2022−JUNE 2025 225
TABLE 211 ELANCO: COMPANY OVERVIEW 227
TABLE 212 ELANCO: PRODUCTS OFFERED 228
TABLE 213 ELANCO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022−JUNE 2025 229
TABLE 214 ELANCO: EXPANSIONS, JANUARY 2022−JUNE 2025 229
TABLE 215 MERCK & CO., INC.: COMPANY OVERVIEW 231
TABLE 216 MERCK & CO., INC.: PRODUCTS OFFERED 232
TABLE 217 MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022−JUNE 2025 233
TABLE 218 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022−JUNE 2025 233
TABLE 219 ANIMAB: COMPANY OVERVIEW 235
TABLE 220 ANIMAB: PRODUCTS OFFERED 235
TABLE 221 ANIMAB: DEALS, JANUARY 2022−JUNE 2025 236
TABLE 222 VAXXINOVA INTERNATIONAL B.V.: COMPANY OVERVIEW 237
TABLE 223 CEVA LOGISTICS: COMPANY OVERVIEW 238
TABLE 224 MABGENESIS INC.: COMPANY OVERVIEW 239
TABLE 225 DECHRA: COMPANY OVERVIEW 240
TABLE 226 BIOGENESIS BAGO: COMPANY OVERVIEW 241
TABLE 227 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 242
TABLE 228 VIRBAC: COMPANY OVERVIEW 243
TABLE 229 BIOVETA, A.S.: COMPANY OVERVIEW 244
TABLE 230 NIPPON ZENYAKU KOGYO CO., LTD.: COMPANY OVERVIEW 245
FIGURE 1 VETERINARY MONOCLONAL ANTIBODIES MARKET SEGMENTATION
AND REGIONAL SCOPE 26
FIGURE 2 VETERINARY MONOCLONAL ANTIBODIES MARKET: YEARS CONSIDERED 28
FIGURE 3 VETERINARY MONOCLONAL ANTIBODIES MARKET: RESEARCH DESIGN 29
FIGURE 4 VETERINARY MONOCLONAL ANTIBODIES MARKET: KEY PRIMARY SOURCES 32
FIGURE 5 VETERINARY MONOCLONAL ANTIBODIES MARKET: INSIGHTS FROM PRIMARIES 33
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 33
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 34
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION 34
FIGURE 9 VETERINARY MONOCLONAL ANTIBODIES MARKET SIZE ESTIMATION:
SUPPLY-SIDE ANALYSIS, 2024 35
FIGURE 10 MONOCLONAL ANTIBODIES IN ANIMAL HEALTH: MARKET SIZE ESTIMATION 36
FIGURE 11 TOP-DOWN APPROACH 38
FIGURE 12 BOTTOM-UP APPROACH 38
FIGURE 13 VETERINARY MONOCLONAL ANTIBODY MARKET: CAGR PROJECTIONS 39
FIGURE 14 DATA TRIANGULATION METHODOLOGY 40
FIGURE 15 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE,
2025 VS. 2030 (USD MILLION) 43
FIGURE 16 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT,
2025 VS. 2030 (USD MILLION) 44
FIGURE 17 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION) 44
FIGURE 18 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA,
2025 VS. 2030 (USD MILLION) 45
FIGURE 19 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 46
FIGURE 20 GEOGRAPHICAL SNAPSHOT OF VETERINARY MONOCLONAL ANTIBODIES MARKET 47
FIGURE 21 INCREASING PREVALENCE OF CHRONIC AND ACUTE DISEASES TO DRIVE MARKET 48
FIGURE 22 CANINES SEGMENT AND US LED NORTH AMERICA MARKET IN 2024 49
FIGURE 23 CANINES SEGMENT TO CAPTURE LARGEST MARKET SHARE DURING FORECAST PERIOD 49
FIGURE 24 LOKIVETMAB (CYTOPOINT) SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 50
FIGURE 25 SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 50
FIGURE 26 DERMATOLOGY SEGMENT TO HAVE LARGEST MARKET SHARE DURING FORECAST PERIOD 51
FIGURE 27 FRANCE TO REGISTER HIGHEST GROWTH IN VETERINARY MONOCLONAL ANTIBODIES MARKET FROM 2025 TO 2030 52
FIGURE 28 VETERINARY MONOCLONAL ANTIBODIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
FIGURE 29 NEW REVENUE POCKETS FOR PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET 61
FIGURE 30 VETERINARY MONOCLONAL ANTIBODIES MARKET: SUPPLY CHAIN ANALYSIS 64
FIGURE 31 VETERINARY MONOCLONAL ANTIBODIES MARKET: ECOSYSTEM ANALYSIS 65
FIGURE 32 VETERINARY MONOCLONAL ANTIBODIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2020–2024 66
FIGURE 33 VETERINARY MONOCLONAL ANTIBODIES MARKET: PATENT ANALYSIS,
JANUARY 2014–MAY 2025 69
FIGURE 34 TOP APPLICANTS FOR VETERINARY MONOCLONAL ANTIBODIES PATENTS,
JANUARY 2014–MAY 2025 70
FIGURE 35 VETERINARY MONOCLONAL ANTIBODIES MARKET: PORTER’S FIVE FORCES ANALYSIS 78
FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 80
FIGURE 37 KEY BUYING CRITERIA, BY END USER 81
FIGURE 38 VETERINARY MONOCLONAL ANTIBODIES MARKET: AI USE CASES 86
FIGURE 39 NORTH AMERICA: VETERINARY MONOCLONAL ANTIBODIES MARKET SNAPSHOT 130
FIGURE 40 ASIA PACIFIC: DOG POPULATION GROWTH, BY COUNTRY, 2024 164
FIGURE 41 ASIA PACIFIC: CAT POPULATION GROWTH, BY COUNTRY, 2024 164
FIGURE 42 REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS IN VETERINARY MONOCLONAL ANTIBODIES MARKET, 2023–2024 207
FIGURE 43 VETERINARY MONOCLONAL ANTIBODIES MARKET SHARE ANALYSIS, 2024 208
FIGURE 44 US: VETERINARY MONOCLONAL ANTIBODIES MARKET SHARE ANALYSIS, 2024 208
FIGURE 45 RANKING OF KEY PLAYERS IN VETERINARY MONOCLONAL
ANTIBODIES MARKET, 2024 209
FIGURE 46 VETERINARY MONOCLONAL ANTIBODIES MARKET:
BRAND/PRODUCT COMPARISON 210
FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 211
FIGURE 48 EV/EBITDA OF KEY VENDORS 211
FIGURE 49 VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 213
FIGURE 50 VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY FOOTPRINT 214
FIGURE 51 VETERINARY MONOCLONAL ANTIBODIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 217
FIGURE 52 ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2024) 223
FIGURE 53 ELANCO: COMPANY SNAPSHOT (2024) 228
FIGURE 54 MERCK & CO., INC.: COMPANY SNAPSHOT (2024) 232